Bhandari Madhavi, Nguyen Sanko, Yazdani Mazyar, Utheim Tor Paaske, Hagesaether Ellen
Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
Front Pharmacol. 2022 May 13;13:903519. doi: 10.3389/fphar.2022.903519. eCollection 2022.
Although numerous nanoparticle formulations have been developed for ocular administration, concerns are being raised about a possible mismatch between potential promises made by the field of nanoparticle research and demonstration of actual therapeutic benefit. Therefore, the primary focus of this present review was to critically assess to what extent nanoencapsulation of ocular drugs improved the therapeutic outcome when treating conditions in the anterior segment of the eye. A systematic search was conducted using Medline, PubMed, and Embase databases as well as Google Scholar for published peer-reviewed articles in English focusing on conventional nanoparticles used as drug delivery systems to the anterior segment of the eye in studies. The major therapeutic outcomes were intraocular pressure, tear secretion, number of polymorphonuclear leucocytes and pupil size. The outcome after encapsulation was compared to the non-encapsulated drug. From the search, 250 results were retrieved. Thirty-eight studies met the inclusion criteria. Rabbits were used as study subjects in all but one study, and the number of animals ranged from 3 to 10. Coated and uncoated liposomes, lipid-based and polymeric nanoparticles, as well as micelles, were studied, varying in both particle size and surface charge, and encapsulating a total of 24 different drugs, including 6 salts. The majority of the studies demonstrated some improvement after nanoencapsulation, but the duration of the benefit varied from less than 1 h to more than 20 h. The most common methods performed in the studies were drug release, transcorneal permeation, and mucin interaction. Nanoparticles that are small and mucoadhesive, often due to positive surface charge, appeared beneficial. Although assays can unravel more of the hidden and sophisticated interplay between the encapsulated drug and the nanoparticle structure, they suffered from a lack of - correlation. Therefore, more research should be focused towards developing predictive models, allowing rational design and systematic optimization of ocular nanoparticles with minimal animal experimentation.
尽管已经开发出许多用于眼部给药的纳米颗粒制剂,但人们对纳米颗粒研究领域所做出的潜在承诺与实际治疗效果的证明之间可能存在的不匹配日益担忧。因此,本综述的主要重点是严格评估眼部药物的纳米包封在治疗眼前节疾病时在多大程度上改善了治疗效果。使用Medline、PubMed和Embase数据库以及谷歌学术进行了系统检索,以查找英文发表的同行评审文章,这些文章聚焦于在研究中用作眼前节药物递送系统的传统纳米颗粒。主要治疗结果包括眼压、泪液分泌、多形核白细胞数量和瞳孔大小。将包封后的结果与未包封的药物进行比较。通过检索,共获得250条结果。38项研究符合纳入标准。除一项研究外,所有研究均使用兔子作为研究对象,动物数量从3只到10只不等。研究了包衣和未包衣的脂质体、基于脂质和聚合物的纳米颗粒以及胶束,它们在粒径和表面电荷方面各不相同,共包封了包括6种盐在内的24种不同药物。大多数研究表明纳米包封后有一定改善,但益处持续时间从不到1小时到超过20小时不等。研究中最常用的方法是药物释放、角膜渗透和粘蛋白相互作用。小尺寸且具有粘膜粘附性的纳米颗粒,通常由于带正表面电荷,似乎有益。尽管分析可以揭示包封药物与纳米颗粒结构之间更多隐藏和复杂的相互作用,但它们缺乏相关性。因此,应更多地致力于开发预测模型,以便在最少动物实验的情况下对眼部纳米颗粒进行合理设计和系统优化。